Shares of Freenome (NASDAQ:FRNM – Get Free Report) have received an average rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $18.00.
A number of equities research analysts recently commented on the company. TD Cowen initiated coverage on Freenome in a research note on Tuesday, August 18th. They set a “buy” rating and a $17.00 price objective for the company. Leerink Partners began coverage on Freenome in a research note on Friday, August 14th. They set an “outperform” rating and a $18.00 price objective on the stock. BTIG Research initiated coverage on Freenome in a report on Monday, August 17th. They set a “buy” rating and a $17.00 price objective on the stock. Jefferies Financial Group initiated coverage on shares of Freenome in a research report on Monday, August 17th. They set a “buy” rating and a $17.00 price objective for the company. Finally, Wall Street Zen upgraded Freenome to a “sell” rating in a report on Saturday, September 26th.
View Our Latest Stock Report on Freenome
Freenome Stock Up 11.9%
Shares of NASDAQ FRNM opened at $14.06 on Wednesday. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -234.29 and a beta of 0.44. Freenome has a 1 year low of $9.97 and a 1 year high of $17.50. The company has a 50-day simple moving average of $14.87.
Freenome Company Profile
Freenome is a biotechnology company developing blood-based tests designed to detect cancer at an early stage. Its platform combines artificial intelligence with multiomics, including genomic, epigenomic and proteomic signals found in blood, to identify patterns associated with cancer.
The company has focused its research and clinical development efforts on screening for colorectal cancer and other common cancers. Freenome’s products are intended to support noninvasive screening and may complement or provide an alternative to certain conventional screening methods, subject to regulatory review and approval.
Founded in 2014, Freenome is headquartered in South San Francisco, California.
Recommended Stories
- Five stocks we like better than Freenome
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.
